Transient inherited antithrombin deficiency: a real phenomenon?

Thromb Haemost 2017; 117(03): 642-643
DOI: 10.1160/TH16-10-0791

Letters to the Editor

Schattauer GmbH

Authors

Martina E. Daly

¹Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
Peter C. Cooper

²Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, Sheffield, UK
Kieron P. Hickey

²Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, Sheffield, UK
Ian Jennings

³UK NEQAS Blood Coagulation, Sheffield, UK
Mike Makris

¹Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK

²Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, Sheffield, UK

References
1 Navarro-Fernández J, de la Morena-Barrio ME, Padilla J. et al. Antithrombin Dublin (p Val30Glu): a relatively common variant with moderate thrombosis risk of causing transient antithrombin deficiency. Thromb Haemost 2016; 116: 146-154.
2 Daly M, O’Meara A, Hallinan FM. Identification and characterization of a new antithrombin III familial variant (AT Dublin) with possible increased frequency in children with cancer. Brit J Haematol 1987; 65: 457-462.
3 Daly M, Bruce D, Perry DJ. et al. Antithrombin Dublin (-3Val?Glu): an N-terminal variant which has an aberrant signal peptidase cleavage site. FEBS Letts 1990; 273: 87-90.
4 Bruce D, Perry DJ, Borg JY. et al. Thromboembolic disease due to thermolabile conformational changes of antithrombin Rouen-VI (187 Asn?Asp). J Clin Invest 1994; 94: 2265-2274.
5 Beauchamp NJ, Pike RN, Daly M. et al. Antithrombins Wibble and Wobble (T85M/K): archetypal conformational diseases with in vivo latent-transition, thrombosis, and heparin activation. Blood 1998; 92: 2696-2706.
6 Jennings I, Kitchen S, Woods TA. et al. Multilaboratory testing in thrombophilia through the United Kingdom National External Quality Assessment Scheme (Blood Coagulation) Quality Assurance Program. Semin Thromb Hemost 2005; 31: 66-72.
7 Puurunen M, Salo P, Engelbarth S. et al. Type II antithrombin deficiency caused by a founder mutation Pro73Leu in the Finnish population: clinical picture. J Thromb Haemost 2013; 11: 1844-1849.